AbbVie
AbbVie returns on capital
Annual and trailing 12-month returns on invested capital, equity and assets.
ROIC
% · Annual / TTM
ROCE
% · Annual / TTM
ROIIC
% · Annual / TTM
ROE
% · Annual / TTM
ROA
% · Annual / TTM
ROIC − WACC
Percentage points · Scenario
Quarterly data
| Fiscal period | Ended | ROIC% | ROCE% | ROIIC% | ROE% | ROA% | ROIC − WACCPercentage points |
|---|---|---|---|---|---|---|---|
| FY 2026 Q2 | Jun 30, 2026 | 20.04% | 17.68% | — | — | 4.63% | 12.1 pp |
| FY 2026 Q1 | Mar 31, 2026 | 15.19% | 15.8% | — | — | 2.67% | 7.3 pp |
| FY 2025 Q4 | Dec 31, 2025 | 15.6% | 16.12% | — | 15,221.82% | 3.14% | 7.7 pp |
| FY 2025 Q3 | Sep 30, 2025 | — | 9.28% | — | 139.12% | 1.72% | — |
| FY 2025 Q2 | Jun 30, 2025 | — | 11.11% | — | 113.21% | 2.7% | — |
| FY 2025 Q1 | Mar 31, 2025 | — | 9.73% | — | 88.36% | 2.94% | — |
| FY 2024 Q4 | Dec 31, 2024 | — | 9.45% | — | 61.94% | 3.17% | — |
| FY 2024 Q3 | Sep 30, 2024 | 15.23% | 13.7% | -23.45% | 56.18% | 3.66% | 7.3 pp |
| FY 2024 Q2 | Jun 30, 2024 | 14.35% | 12.08% | — | 54.04% | 3.85% | 6.5 pp |
| FY 2024 Q1 | Mar 31, 2024 | 15.37% | 11.93% | — | 56.02% | 4.23% | 7.5 pp |
| FY 2023 Q4 | Dec 31, 2023 | 15.5% | 12.38% | — | 34.91% | 3.56% | 7.6 pp |
| FY 2023 Q3 | Sep 30, 2023 | 18.4% | 14.34% | — | 46.15% | 4.69% | 10.5 pp |
| FY 2023 Q2 | Jun 30, 2023 | 20.05% | 16.41% | — | 62.83% | 6.24% | 12.1 pp |
| FY 2023 Q1 | Mar 31, 2023 | 17.86% | 14.86% | — | 51.05% | 5.46% | 10 pp |
| FY 2022 Q4 | Dec 31, 2022 | 20.72% | 16.43% | — | 72.15% | 8.3% | 12.8 pp |
| FY 2022 Q3 | Sep 30, 2022 | 20.6% | 15.45% | — | 90.41% | 9.24% | 12.7 pp |
| FY 2022 Q2 | Jun 30, 2022 | 18.91% | 15.26% | — | 92.45% | 8.68% | 11 pp |
| FY 2022 Q1 | Mar 31, 2022 | 19.02% | 16.17% | — | 82.81% | 8.5% | 11.1 pp |
| FY 2021 Q4 | Dec 31, 2021 | 18.42% | 15.37% | — | 80.52% | 7.77% | 10.5 pp |
| FY 2021 Q3 | Sep 30, 2021 | — | 13.51% | — | 51.85% | 5.05% | — |
| FY 2021 Q2 | Jun 30, 2021 | — | 12.74% | — | 48.43% | 4.48% | — |
| FY 2021 Q1 | Mar 31, 2021 | — | 12.28% | — | 162.03% | 4.27% | — |
| FY 2020 Q4 | Dec 31, 2020 | — | 11.63% | — | 185.81% | 3.85% | — |
| FY 2020 Q3 | Sep 30, 2020 | 18.78% | 13.82% | — | 208.18% | 7.06% | 10.9 pp |
| FY 2020 Q2 | Jun 30, 2020 | 16.98% | 13.24% | — | 225.17% | 6.73% | 9.1 pp |
| FY 2020 Q1 | Mar 31, 2020 | 59.44% | 23.09% | — | — | 11.4% | 51.5 pp |
| FY 2019 Q4 | Dec 31, 2019 | 56.22% | 22.45% | — | — | 10.62% | 48.3 pp |
| FY 2019 Q3 | Sep 30, 2019 | — | 14.21% | — | — | 5.18% | — |
| FY 2019 Q2 | Jun 30, 2019 | — | 16.85% | — | — | 6.93% | — |
| FY 2019 Q1 | Mar 31, 2019 | — | 13.64% | — | — | 8.5% | — |
| FY 2018 Q4 | Dec 31, 2018 | — | 13.26% | — | — | 8.74% | — |
| FY 2018 Q3 | Sep 30, 2018 | 27.94% | 19.92% | — | 399.95% | 11.21% | 20 pp |
| FY 2018 Q2 | Jun 30, 2018 | 24.04% | 20.5% | — | 487.4% | 10.03% | 16.1 pp |
| FY 2018 Q1 | Mar 31, 2018 | 22.07% | 18.47% | — | 148.57% | 9.45% | 14.2 pp |
| FY 2017 Q4 | Dec 31, 2017 | 18.95% | 17.37% | — | 108.56% | 7.76% | 11.1 pp |
| FY 2017 Q3 | Sep 30, 2017 | 21.5% | 17.92% | — | 100.67% | 9.82% | 13.6 pp |
| FY 2017 Q2 | Jun 30, 2017 | 20.67% | 17.42% | — | 113.13% | 9.86% | 12.8 pp |
| FY 2017 Q1 | Mar 31, 2017 | 22.16% | 19.07% | 12.17% | 130.55% | 10.57% | 14.3 pp |
| FY 2016 Q4 | Dec 31, 2016 | 22.28% | 19.06% | 13.66% | 138.05% | 9.99% | 14.4 pp |
| FY 2016 Q3 | Sep 30, 2016 | 21.78% | 17.65% | 33.52% | 107.15% | 10.01% | 13.9 pp |
| FY 2016 Q2 | Jun 30, 2016 | 20.06% | 17.23% | 44.55% | 102.66% | 9.45% | 12.2 pp |
| FY 2016 Q1 | Mar 31, 2016 | 33.57% | 27.69% | 17.73% | 181.93% | 13.62% | 25.7 pp |
| FY 2015 Q4 | Dec 31, 2015 | 32.76% | 25.85% | 17.44% | 180.9% | 12.76% | 24.9 pp |
| FY 2015 Q3 | Sep 30, 2015 | 19.4% | 14.77% | -1.73% | 59.26% | — | 11.5 pp |
| FY 2015 Q2 | Jun 30, 2015 | 15.58% | 12.5% | -7.07% | 38.87% | — | 7.7 pp |
| FY 2015 Q1 | Mar 31, 2015 | 27.86% | 19.67% | — | 59.8% | — | 20 pp |
| FY 2014 Q4 | Dec 31, 2014 | 28.34% | 17.74% | — | 56.91% | 6.25% | 20.4 pp |
| FY 2014 Q3 | Sep 30, 2014 | 38.88% | 24.82% | — | 90.29% | — | 31 pp |
| FY 2014 Q2 | Jun 30, 2014 | 43.25% | 26.34% | — | 95.03% | — | 35.3 pp |
| FY 2014 Q1 | Mar 31, 2014 | 39.99% | 26.65% | — | 108.18% | — | 32.1 pp |
| FY 2013 Q4 | Dec 31, 2013 | — | — | — | — | — | — |
| FY 2013 Q3 | Sep 30, 2013 | — | — | — | — | — | — |
| FY 2013 Q2 | Jun 30, 2013 | — | — | — | — | — | — |
| FY 2013 Q1 | Mar 31, 2013 | — | — | — | — | — | — |
Sources and calculations
Financial inputs from company filings. Last checked Oct 18, 2026. A dash means missing inputs or an undefined calculation.
Period changes use the preceding fiscal quarter or year. Percentage changes divide by the absolute prior value; a zero or missing baseline has no percentage change. Percentage metrics show changes in percentage points.
Quarterly returns use trailing 12-month earnings and period-end balances averaged with the same fiscal quarter one year earlier. NOPAT uses the reported effective tax rate only when pretax profit is positive and the rate is between 0 and 100%. WACC starts at 7.9%, rounded from the Pharmaceuticals benchmark in NYU Stern · January 2026. It is an editable US sector proxy applied across history, not a company estimate; foreign reporting currencies also need a currency-specific assessment.
Market prices: Yahoo Finance · ABBV, USD. Latest completed close Sep 25, 2026. Price data retrieved Sep 28, 2026.
- ROIC
- NOPAT / average invested capital × 100. NOPAT = operating income × (1 − effective tax rate). Invested capital = equity including noncontrolling interests + debt − cash and equivalents. Average uses period end and one year earlier.
- ROCE
- Operating income / average (assets − current liabilities) × 100, using period end and one year earlier.
- ROIIC
- Year-over-year change in annual/TTM NOPAT / positive year-over-year change in invested capital × 100. Capital reductions and missing inputs yield unavailable values.
- ROE
- Earnings attributable to owners / average equity attributable to owners × 100, using period end and one year earlier.
- ROA
- Net income / average total assets × 100, using period end and one year earlier.
- ROIC − WACC
- ROIC less your WACC assumption, in percentage points. The same scenario rate is applied across history; it is not a reported or historical company WACC.